STUDIES ON CEFROXADINE (CGP-9000) FOR THE TREATMENT OF RESPIRATORY INFECTIONS

• Published in: CHEMOTHERAPY Vol. 28; no. Supplement3; pp. 266 - 275
• Main Authors: SOEJIMA, RINZO, TANO, YOSHIHIKO, NIKI, YOSHITO, MATSUSHIMA, TOSHIHARU, KOBAYASHI, TAKEHIKO, OKIMOTO, JIRO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1980
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.28.Supplement3_266

Cefroxadine (CGP-9000, CXD) is an orally active cephalosporin antibiotic which has been newly developed by CIBA-GEIGY. Its antibacterial activity against clinically isolated organisms, absorption and excretion after oral administration and clinical responses of patients with respiratory infections were studied. The MIC of CXD against Staphylococcus aureus ranged from 3.13 to 25μg/ml, which was comparable to that of CEX, the peak MIC of the former against E. coli and Klebsiella pneumoniae was 6.25μg/ml, which was slightly superior to that of the latter. Against Proteus mirabilis, the two antibiotics showed essentially same antibacterial activity. The MICs of CXD were more than 100μg/ml in almost all strains of other microorganisms such as Proteus vulgaris, Serratia marcescens, Pseudomonas cepacia and Acinetobacter. The peak blood level of CXD following the oral administration of 250mg prior to breakfast reached 9.6 to 17.2μg/ml (mean 12.1μg/ml) 2hours after administration, and its urinary recovery in 6-hour urine ranged from 52 to 93%(mean 78%). Twelve patients with respiratory infections were given 500mg of CXD three times a day for 4-44 days. Of them, the drug efficacy could be evaluated in 11 patients. It was excellent in 2 cases, good in 6, fairly good in 1 and poor in 2. Neither adverse side-effect nor abnormal laboratory finding occurred in all cases. The obtained results suggest that CXD is a useful antibiotic.